Table 1 Demographics and clinical characteristics
GAD+MDD+ (N = 559) | GAD+MDD- (N = 422) | Control (N = 336) | ||||
|---|---|---|---|---|---|---|
PPS+ (N = 436) | PPS- (N = 123) | PPS+ (N = 249) | PPS- (N = 173) | PPS+ (N = 95) | PPS- (N = 241) | |
Gender, female, n (%)* | 338 (77.5) | 95 (77.2) | 196 (78.7)b | 118 (68.2) | 64 (67.4)c | 119 (49.4) |
Age (years), mean (SD)** | 53.3 (14.7)d | 48.3 (13.8) | 51.5 (14.7)d | 47.4 (13.8) | 54.4 (17.4)d | 49.4 (17.1) |
Medical comorbidities, n (%) | ||||||
At least one* | 329 (75.5)a | 59 (48.0) | 187 (75.1)b | 81 (46.8) | 66 (69.5)c | 122 (50.6) |
Hypertension † | 156 (35.8)a | 29 (23.6) | 76 (30.5) | 38 (22.0) | 28 (29.5) | 72 (29.9) |
Diabetes mellitus †† | 56 (12.8)a | 6 (4.9) | 28 (11.2) | 12 (6.9) | 7 (7.4) | 18 (7.5) |
Coronary artery disease ‡ | 29 (6.7) | 4 (3.3) | 8 (3.2) | 3 (1.7) | 4 (4.2) | 8 (3.3) |
Degenerative osteoarthritis* | 116 (26.6)a | 10 (8.1) | 61 (24.5)b | 21 (12.1) | 29 (30.5)c | 25 (10.4) |
Psychiatric comorbidities, n (%) | ||||||
At least one* | 146 (33.5)a | 28 (22.8) | 62 (24.9) | 30 (17.3) | 4 (4.2) | 3 (1.2) |
CGI-Severity, mean (SD)** | 4.5 (0.9)d | 3.8 (1.0) | 3.6 (1.0)d | 2.9 (1.1) | 2.0 (1.2)d | 1.3 (0.7) |
Current medication, n (%) | ||||||
Antidepressants* | 153 (35.1) | 43 (35.0) | 44 (17.7) | 30 (17.3) | 2 (2.1) | 4 (1.7) |
Benzodiazepines* | 205 (47.0)a | 42 (34.1) | 102 (41.0)b | 46 (26.6) | 8 (8.4) | 10 (4.1) |
Analgesics* | 265 (60.8)a | 36 (29.3) | 140 (56.2)b | 36 (20.8) | 55 (57.9)c | 38 (15.8) |
NSAIDs* | 168 (38.5)a | 21 (17.1) | 96 (38.6)b | 32 (18.5) | 37 (38.9)c | 18 (7.5) |
Analgesic/NSAIDs* | 301 (69.0)a | 44 (35.8) | 162 (65.1)b | 53(30.6) | 66 (69.5)c | 46 (19.1) |